ProMIS Neurosciences (NASDAQ:PMN – Get Free Report) and Regulus Therapeutics (NASDAQ:RGLS – Get Free Report) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, risk, dividends, profitability, institutional ownership and valuation.
Profitability
This table compares ProMIS Neurosciences and Regulus Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| ProMIS Neurosciences | N/A | -587.38% | -133.87% |
| Regulus Therapeutics | N/A | -55.47% | -49.37% |
Analyst Ratings
This is a summary of recent ratings and recommmendations for ProMIS Neurosciences and Regulus Therapeutics, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| ProMIS Neurosciences | 0 | 0 | 1 | 0 | 3.00 |
| Regulus Therapeutics | 0 | 1 | 5 | 0 | 2.83 |
Earnings & Valuation
This table compares ProMIS Neurosciences and Regulus Therapeutics”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| ProMIS Neurosciences | $10,000.00 | 2,464.93 | -$13.21 million | ($0.74) | -1.76 |
| Regulus Therapeutics | N/A | N/A | -$30.04 million | ($1.46) | -1.06 |
ProMIS Neurosciences has higher revenue and earnings than Regulus Therapeutics. ProMIS Neurosciences is trading at a lower price-to-earnings ratio than Regulus Therapeutics, indicating that it is currently the more affordable of the two stocks.
Institutional & Insider Ownership
50.1% of ProMIS Neurosciences shares are held by institutional investors. Comparatively, 92.4% of Regulus Therapeutics shares are held by institutional investors. 6.4% of ProMIS Neurosciences shares are held by insiders. Comparatively, 4.4% of Regulus Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
Volatility & Risk
ProMIS Neurosciences has a beta of 0.62, meaning that its share price is 38% less volatile than the S&P 500. Comparatively, Regulus Therapeutics has a beta of 1.63, meaning that its share price is 63% more volatile than the S&P 500.
Summary
Regulus Therapeutics beats ProMIS Neurosciences on 7 of the 12 factors compared between the two stocks.
About ProMIS Neurosciences
ProMIS Neurosciences, Inc. discovers and develops antibody therapies and therapeutic vaccines neurodegenerative diseases and other misfolded protein diseases in Canada. The company's proprietary discovery platform comprises ProMIS and Collective Coordinates algorithms to predict novel targets known as disease specific epitopes on the molecular surface of misfolded proteins. Its lead product candidates include PMN310, a monoclonal antibody (mAb) for toxic oligomers in AD; PMN267, a TDP-43; and PMN442, a mAb targeting toxic a-syn oligomers and seeding fibrils. The company was formerly known as Amorfix Life Sciences Ltd. and changed its name to ProMIS Neurosciences, Inc. in July 2015. ProMIS Neurosciences, Inc. was incorporated in 2004 and is headquartered in Toronto, Canada.
About Regulus Therapeutics
Regulus Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RGLS8429, an anti-miR next generation oligonucleotide targeting miR-17, which is in Phase 1b clinical trial for the treatment of autosomal dominant polycystic kidney disease. The company is also developing a pipeline of preclinical drug products for target organ-selective delivery strategies. Regulus Therapeutics Inc. was incorporated in 2007 and is headquartered in San Diego, California.
Receive News & Ratings for ProMIS Neurosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProMIS Neurosciences and related companies with MarketBeat.com's FREE daily email newsletter.
